Nutritional compositions of non-psychotropic cannabinoids and xanthines
This invention discloses a nutritional composition of matter that effectively provide a nootropic effect beyond the effects simple obtain by cannabinoids alone. Effectively reduce anxiety due to ingestion of xanthines containing oral products. Similarly reduce the side effects associated with the exogenous ingestion of yohimbine and its derivatives.
1. A nutritional composition consisting essentially of:
a first component consisting of 1 to 300 mg/dose of cannabidiol, cannabinol, or a mixture thereof;
a second component consisting of 1 to 400 mg/dose of caffeine, theobromine, or a mixture thereof;
a third component consisting of 1 to 30 mg/dose of yohimbine, yohimbine HCl, yohimbine monoglycine ester, yohimbine alkyl amine, or a mixture thereof; and
an aqueous carrier;
wherein the first component, the second component, and the third component are the only active ingredients.
2. The nutritional composition of claim 1 , wherein said composition is in the form of an orally administrable liquid composition.
3. An orally administrable liquid composition, comprising a mixture of:
a nutritional composition consisting essentially of:
a first component consisting of 1 to 300 mg/dose of cannabidiol, cannabinol, or a mixture thereof;
a second component consisting of 1 to 400 mg/dose of caffeine, theobromine, or a mixture thereof;
a third component consisting of 1 to 30 mg/dose of yohimbine, yohimbine HCl, yohimbine monoglycine ester, yohimbine alkyl amine, or a mixture thereof;
wherein the first component, the second component, and the third component are the only active ingredients in the nutritional composition; and
a medium comprising water, fruit juice, yogurt, or pudding.
4. The nutritional composition of claim 1 , wherein said composition is in the form of a dispersion or suspension of a powder in an aqueous medium.
5. A method for imparting a nootropic effect to a mammal in need thereof, the method comprising: administering an effective amount of a nutritional composition to a mammal in need thereof; and imparting a nootropic effect beyond effects obtained by cannabinoids alone;
wherein the nutritional composition consists essentially of:
a first component consisting of 1 to 300 mg/dose of cannabidiol, cannabinol, or a mixture thereof;
a second component consisting of 1 to 400 mg/dose of caffeine, theobromine, or a mixture thereof;
a third component consisting of 1 to 30 mg/dose of yohimbine, yohimbine HCl, yohimbine monoglycine ester, yohimbine alkyl amine, or a mixture thereof; and
an aqueous carrier;
wherein the first component, the second component, and the third component are the only active ingredients in the nutritional composition.
6. The method of claim 5 , wherein said administering is once a day over a period of treatment of one-eight weeks.
7. The method of claim 5 , wherein the method includes, prior to said administering, providing said nutritional composition is in a powder form; dispersing the composition in water or in a suspension in a suitable aqueous vehicle or carrier to form a liquid composition; and the administering followed by orally ingesting said liquid composition, or in a snack composition.
8. The method of claim 5 , wherein the method includes, prior to said administering, providing said nutritional composition is in a powder form; dispersing the composition in [[a]] the aqueous carrier fruit juicc, yogurt or pudding; and the administering followed by orally ingesting said liquid composition.
9. A composition for treating epilepsy, anxiety, sleep disorders, psychosis and movement disorders, relief of pain, emesis, reduce food intake, anti-proliferative/pro-apoptotic effects, bacterial infection, inflammation, or psoriasis, consisting essentially of:
a first component consisting of 1 to 300 mg/dose of cannabidiol, cannabinol, or a mixture thereof;
a second component consisting of 1 to 400 mg/dose of a methylxanthine selected from the group consisting of caffeine, aminophylline, 3-isobutyl-lmethylxanthine, paraxanthine, pentoxifylline, theobromine, theophylline, and a mixture thereof; and
a third component consisting of Yohimbine, yohimbine HCl, yohimbine monoglycine ester, yohimbine alkyl amine, or a mixture thereof, and
an aqueous carrier:
wherein the first component, the second component, and the third component are the only active ingredients.
10. An orally administrable liquid composition, comprising a mixture of the composition of claim 9 , and water, fruit juice, yogurt, or pudding.
11. An orally administrable liquid composition, comprising the composition of claim 9 .
12. An orally administrable liquid composition, comprising the composition of claim 9 , wherein said orally administrable liquid composition is in the form of a dispersion or suspension of a powder in an aqueous medium.
13. The composition of claim 9 , wherein:
the methylxanthine is caffeine.
14. The composition of claim 13 , wherein said composition is in the form of an orally administrable liquid composition.
15. A method for treating epilepsy, anxiety, sleep disorders, psychosis and movement disorders, relief of pain, emesis, reduce food intake, anti-proliferative/pro-apoptotic effects, bacterial infection, inflammation, or psoriasis, the method comprising: administering an effective amount of a nutritional composition to a mammal in need thereof;
wherein the nutritional composition consists essentially of:
a first component consisting of 1 to 300 mg/dose of cannabidiol, cannabinol, or a mixture thereof;
a second component consisting of 1 to 400 mg/dose of caffeine, theobromine, or a mixture thereof;
a third component consisting of 1 to 30 mg/dose of yohimbine, yohimbine HCl, yohimbine monoglycine ester, yohimbine alkyl amine, or a mixture thereof; and
an aqueous carrier;
wherein the first component, the second component, and the third component are the only active ingredients in the nutritional composition.